Supplemental material
AssayResult: 3.1
AssayResultAssertion: Abnormal
Comment: See Table S3 for details; The blood sample used to test this variant was derived from an individual carrying the c.723del variant in combination with the c.*1175A>C variant in heterozygosity.
Supplemental material
AssayResult: 5.5, 5.7
AssayResultAssertion: Abnormal
Comment: See Table S3 for details; The blood sample used to test this variant was derived from an individual carrying the variant in homozygosity.
Supplemental material
AssayResult: 20.5
AssayResultAssertion: Normal
Comment: See Table S3 for details
Supplemental material
AssayResult: 3.4
AssayResultAssertion: Abnormal
Comment: See Table S3 for details
Supplemental material
AssayResult: 2.6, 4.8
AssayResultAssertion: Abnormal
Comment: See Table S3 for details
Supplemental material
AssayResult: 3.8
AssayResultAssertion: Abnormal
Comment: See Table S3 for details; This variant was reported as c.323_235del but assumed to be c.323_325del, which corresponds to the reported protein change (p.(Gly108_Phe109delinsVal)).
Supplemental material
AssayResult: 4, 5
AssayResultAssertion: Abnormal
Comment: See Table S3 for details
Supplemental material
AssayResult: 5.8, 6.1
AssayResultAssertion: Abnormal
Comment: See Table S3 for details
Supplemental material
AssayResult: 5.3
AssayResultAssertion: Abnormal
Comment: See Table S3 for details
Supplemental material
AssayResult: 5.1
AssayResultAssertion: Abnormal
Comment: See Table S3 for details
Supplemental material
AssayResult: 17.1
AssayResultAssertion: Normal
Comment: See Table S3 for details
Supplemental material
AssayResult: 3.2
AssayResultAssertion: Abnormal
Comment: See Table S3 for details
Supplemental material
AssayResult: 3.5
AssayResultAssertion: Abnormal
Comment: See Table S3 for details
Supplemental material
AssayResult: 4.1
AssayResultAssertion: Abnormal
Comment: See Table S3 for details
Supplemental material
AssayResult: 2.9
AssayResultAssertion: Abnormal
Comment: See Table S3 for details
Supplemental material
AssayResult: 6.1
AssayResultAssertion: Abnormal
Comment: See Table S3 for details
Supplemental material
AssayResult: 12.9
AssayResultAssertion: Normal
Comment: See Table S3 for details
Supplemental material
AssayResult: 4.7
AssayResultAssertion: Abnormal
Comment: See Table S3 for details
Supplemental material
AssayResult: 7.1, 6.0
AssayResultAssertion: Abnormal
Comment: See Table S3 for details
Supplemental material
AssayResult: 3.1
AssayResultAssertion: Abnormal
Comment: See Table S3 for details
Supplemental material
AssayResult: 5.4
AssayResultAssertion: Abnormal
Comment: See Table S3 for details
Supplemental material
AssayResult: 5
AssayResultAssertion: Abnormal
Comment: See Table S3 for details
Supplemental material
AssayResult: 4.8
AssayResultAssertion: Abnormal
Comment: See Table S3 for details
Supplemental material
AssayResult: 3.8
AssayResultAssertion: Abnormal
Comment: See Table S3 for details
Supplemental material
AssayResult: 3.2
AssayResultAssertion: Abnormal
Comment: See Table S3 for details
Supplemental material
AssayResult: 82
AssayResultAssertion: Normal
Comment: See Table S2 for details
Supplemental material
AssayResult: 80
AssayResultAssertion: Normal
Comment: See Table S2 for details
Supplemental material
AssayResult: 69
AssayResultAssertion: Normal
Comment: See Table S2 for details
Supplemental material
AssayResult: 99
AssayResultAssertion: Normal
Comment: See Table S2 for details
Supplemental material
AssayResult: 98
AssayResultAssertion: Normal
Comment: See Table S2 for details
Supplemental material
AssayResult: 77
AssayResultAssertion: Normal
Comment: See Table S2 for details
Supplemental material
AssayResult: 105
AssayResultAssertion: Normal
Comment: See Table S2 for details
Supplemental material
AssayResult: 96
AssayResultAssertion: Normal
Comment: See Table S2 for details
Supplemental material
AssayResult: 104
AssayResultAssertion: Normal
Comment: See Table S2 for details
Supplemental material
AssayResult: 99
AssayResultAssertion: Normal
Comment: See Table S2 for details
Supplemental material
AssayResult: 83
AssayResultAssertion: Normal
Comment: See Table S2 for details
Supplemental material
AssayResult: 91
AssayResultAssertion: Normal
Comment: See Table S2 for details
Supplemental material
AssayResult: 86
AssayResultAssertion: Normal
Comment: See Table S2 for details
Supplemental material
AssayResult: 56
AssayResultAssertion: Normal
Comment: See Table S2 for details
Supplemental material
AssayResult: 61
AssayResultAssertion: Normal
Comment: See Table S2 for details
Supplemental material
AssayResult: 51
AssayResultAssertion: Normal
Comment: See Table S2 for details
Supplemental material
AssayResult: 66
AssayResultAssertion: Normal
Comment: See Table S2 for details
Supplemental material
AssayResult: 60
AssayResultAssertion: Normal
Comment: See Table S2 for details
Supplemental material
AssayResult: 65
AssayResultAssertion: Normal
Comment: See Table S2 for details
Supplemental material
AssayResult: 66
AssayResultAssertion: Normal
Comment: See Table S2 for details
Supplemental material
AssayResult: 45
AssayResultAssertion: Normal
Comment: See Table S2 for details
Supplemental material
AssayResult: 58
AssayResultAssertion: Normal
Comment: See Table S2 for details
Supplemental material
AssayResult: 49
AssayResultAssertion: Normal
Comment: See Table S2 for details
Supplemental material
AssayResult: 83
AssayResultAssertion: Normal
Comment: See Table S2 for details
Supplemental material
AssayResult: 84
AssayResultAssertion: Normal
Comment: See Table S2 for details
Supplemental material
AssayResult: 91
AssayResultAssertion: Normal
Comment: See Table S2 for details
Supplemental material
AssayResult: 94
AssayResultAssertion: Normal
Comment: See Table S2 for details
Supplemental material
AssayResult: 97
AssayResultAssertion: Normal
Comment: See Table S2 for details
Supplemental material
AssayResult: 98
AssayResultAssertion: Normal
Comment: See Table S2 for details
Supplemental material
AssayResult: 96
AssayResultAssertion: Normal
Comment: See Table S2 for details
Supplemental material
AssayResult: 105
AssayResultAssertion: Normal
Comment: See Table S2 for details
Supplemental material
AssayResult: 6.4
AssayResultAssertion: Abnormal
Comment: See Table S2 for details
Supplemental material
AssayResult: 6.8
AssayResultAssertion: Abnormal
Comment: See Table S2 for details
Supplemental material
AssayResult: 7.1
AssayResultAssertion: Abnormal
Comment: See Table S2 for details
Supplemental material
AssayResult: 7.7
AssayResultAssertion: Abnormal
Comment: See Table S2 for details
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.572C>G p.(Pro191Arg)
Supplemental material
AssayResult: 3.5
AssayResultAssertion: Abnormal
Comment: See Table S2 for details
Supplemental material
AssayResult: 3.1
AssayResultAssertion: Abnormal
Comment: See Table S2 for details
Supplemental material
AssayResult: 5
AssayResultAssertion: Abnormal
Comment: See Table S2 for details
Supplemental material
AssayResult: 4.4
AssayResultAssertion: Abnormal
Comment: See Table S2 for details
Supplemental material
AssayResult: 4.2
AssayResultAssertion: Abnormal
Comment: See Table S2 for details
Supplemental material
AssayResult: 4.1
AssayResultAssertion: Abnormal
Comment: See Table S2 for details
Supplemental material
AssayResult: 3.5
AssayResultAssertion: Abnormal
Comment: See Table S2 for details
Supplemental material
AssayResult: 4.9
AssayResultAssertion: Abnormal
Comment: See Table S2 for details
Supplemental material
AssayResult: 5.4
AssayResultAssertion: Abnormal
Comment: See Table S2 for details
Supplemental material
AssayResult: 6.7
AssayResultAssertion: Abnormal
Comment: See Table S2 for details
Supplemental material
AssayResult: 10.8
AssayResultAssertion: Abnormal
Comment: See Table S2 for details
Supplemental material
AssayResult: 4.9
AssayResultAssertion: Abnormal
Comment: See Table S2 for details
Supplemental material
AssayResult: 4.9
AssayResultAssertion: Abnormal
Comment: See Table S2 for details
Supplemental material
AssayResult: 8.6
AssayResultAssertion: Abnormal
Comment: See Table S2 for details
Supplemental material
AssayResult: 4
AssayResultAssertion: Abnormal
Comment: See Table S2 for details
Supplemental material
AssayResult: 6
AssayResultAssertion: Abnormal
Comment: See Table S2 for details
Supplemental material
AssayResult: 5.4
AssayResultAssertion: Abnormal
Comment: See Table S2 for details
Supplemental material
AssayResult: 5.8
AssayResultAssertion: Abnormal
Comment: See Table S2 for details
Supplemental material
AssayResult: 7.1
AssayResultAssertion: Abnormal
Comment: See Table S2 for details
Supplemental material
AssayResult: 5.5
AssayResultAssertion: Abnormal
Comment: See Table S2 for details
Supplemental material
AssayResult: 2.8
AssayResultAssertion: Abnormal
Comment: See Table S2 for details
Supplemental material
AssayResult: 2
AssayResultAssertion: Abnormal
Comment: See Table S2 for details
Supplemental material
AssayResult: 2.8
AssayResultAssertion: Abnormal
Comment: See Table S2 for details
Supplemental material
AssayResult: 3.1
AssayResultAssertion: Abnormal
Comment: See Table S2 for details
Supplemental material
AssayResult: 5.6
AssayResultAssertion: Abnormal
Comment: See Table S2 for details
Supplemental material
AssayResult: 3.5
AssayResultAssertion: Abnormal
Comment: See Table S2 for details
Supplemental material
AssayResult: 5.8
AssayResultAssertion: Abnormal
Comment: See Table S2 for details
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.*1175A>C
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.-117G>T
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.792_794del p.(Leu265del)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.393_395del p.(Asn131del)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.323_325del p.(Gly108_Phe109delinsVal)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.1054G>T p.(Asp352Tyr)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.1043T>C p.(Leu348Ser)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.847C>T p.(Arg283Cys)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.833C>G p.(Pro278Arg)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.329G>A p.(Arg110His)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.472C>T p.(Arg158Cys)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.402T>G p.(Phe134Leu)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.723del p.(Cys242Alafs*5)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.314G>A p.(Gly105Asp)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.215C>A p.(Pro72His)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.704A>G p.(Asn235Ser)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.770del p.(Leu257Argfs*88)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.375G>A p.?
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.542G>A p.(Arg181His)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.1010G>A p.(Arg337His)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.910A>G p.(Thr304Ala)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.904G>A p.(Gly302Arg)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.455del p.(Pro152Argfs*18)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.869G>A p.(Arg290His)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.845G>C p.(Arg282Pro)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.685T>C p.(Cys229Arg)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.646G>A p.(Val216Met)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.578A>C p.(His193Pro)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.577C>G p.(His193Asp)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.523C>G p.(Arg175Gly)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.323G>A p.(Gly108Asp)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.31G>C p.(Glu11Gln)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.820del p.(Val274Phefs*71)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.690del p.(Thr231Profs*16)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.673-2A>G p.?
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.632_641del p.(Thr211Ilefs*33)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.491_494del p.(Lys164Serfs*5)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.742C>T p.(Arg248Trp)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.323_329dup p.(Leu111Phefs*40)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.216dup p.(Val73Argfs*76)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.818G>A p.(Arg273His)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.743G>A p.(Arg248Gln)
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM_000546.5:c.524G>A p.(Arg175His)
Supplemental material
AssayResult: 52
AssayResultAssertion: Abnormal
Comment: See Table S3 for details; The blood sample used to test this variant was derived from an individual carrying the c.723del variant in combination with the c.*1175A>C variant in heterozygosity.
We analysed a total of 82 blood samples derived from 77 individuals (online supplemental table 3). These 77 individuals corresponded either to new index cases suspected to harbour a pathogenic TP53 variant or to relatives of index cases harbouring TP53 variants.
HGVS: NM000546.5:c.(?-202)(*1207?)del p.?
Comment: A CAID could not be generated for this deletion variant with uncertain breakpoints.
Travel bans aren’t an effective response to the new Covid variant | Angela Rasmussen. (2020, December 23). The Guardian. http://www.theguardian.com/commentisfree/2020/dec/23/travel-bans-effective-new-covid-variant
Here’s what we know about the new variant of coronavirus | Sharon Peacock. (2020, December 22). The Guardian. http://www.theguardian.com/commentisfree/2020/dec/22/new-variant-coronavirus-genomic-sars-cov-2-pandemic
Facebook, Twitter, options, S. more sharing, Facebook, Twitter, LinkedIn, Email, URLCopied!, C. L., & Print. (2021, February 23). California’s coronavirus strain looks increasingly dangerous: ‘The devil is already here’. Los Angeles Times. https://www.latimes.com/science/story/2021-02-23/california-homegrown-coronavirus-strain-looks-increasingly-transmissible-and-dangerous
Callaway, E. (2021). ‘A bloody mess’: Confusion reigns over naming of new COVID variants. Nature, 589(7842), 339–339. https://doi.org/10.1038/d41586-021-00097-w
Vaccinations Could Limit Further Mutations. (n.d.). Retrieved 18 February 2021, from https://brief19.com/2021/02/17/brief
Lawton, G. (n.d.). Exclusive: Two variants have merged into heavily mutated coronavirus. New Scientist. Retrieved 17 February 2021, from https://www.newscientist.com/article/2268014-exclusive-two-variants-have-merged-into-heavily-mutated-coronavirus/
Zimmer, C. (2021, February 14). 7 Virus Variants Found in U.S. Carrying the Same Mutation. The New York Times. https://www.nytimes.com/2021/02/14/health/coronavirus-variants-evolution.html
Hodcroft, E. B., Domman, D. B., Oguntuyo, K., Snyder, D. J., Diest, M. V., Densmore, K. H., Schwalm, K. C., Femling, J., Carroll, J. L., Scott, R. S., Whyte, M. M., Edwards, M. D., Hull, N. C., Kevil, C. G., Vanchiere, J. A., Lee, B., Dinwiddie, D. L., Cooper, V. S., & Kamil, J. P. (2021). Emergence in late 2020 of multiple lineages of SARS-CoV-2 Spike protein variants affecting amino acid position 677. MedRxiv, 2021.02.12.21251658. https://doi.org/10.1101/2021.02.12.21251658
Mannix, L. (2021, February 8). Where did these COVID-19 variants come from – and what are they? The Sydney Morning Herald. https://www.smh.com.au/national/what-do-new-variants-of-the-coronavirus-mean-for-us-20210126-p56wuo.html
Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England. (2020, December 23). CMMID Repository. https://cmmid.github.io/topics/covid19/uk-novel-variant.html
Cormier, Z. (n.d.). The Second-Generation COVID Vaccines Are Coming. Scientific American. Retrieved 11 February 2021, from https://www.scientificamerican.com/article/the-second-generation-covid-vaccines-are-coming/
Covid vaccines extremely safe, finds UK regulator. (2021, February 5). BBC News. https://www.bbc.com/news/health-55946912
Shen, X., Tang, H., McDanal, C., Wagh, K., Fischer, W. M., Theiler, J., Yoon, H., Li, D., Haynes, B. F., Saunders, K. O., Gnanakaran, S., Hengartner, N. W., Pajon, R., Smith, G., Dubovsky, F., Glenn, G. M., Korber, B. T., & Montefiori, D. C. (2021). SARS-CoV-2 Variant B.1.1.7 is Susceptible to Neutralizing Antibodies Elicited by Ancestral Spike Vaccines (SSRN Scholarly Paper ID 3777473). Social Science Research Network. https://papers.ssrn.com/abstract=3777473
En cas de survenue d’un cas confirmé portant la variante britannique du SARS-CoV-2Conformément à l’avis du Conseil Scientifique, la confirmation d’un cas de variante britannique du virus SARS-CoV2 dans une classe doit conduire à la fermeture de la classe, dans les établissements d’enseignement du premier degré et du second degré. Les élèves de la classe sont donc assimilés à des contacts à risque. L’identification des contacts à risque parmi les personnels se fait dans les conditions décrites selon les règles définies par Santé publique France
KupferschmidtJan. 15, K., 2021, & Pm, 4:55. (2021, January 15). New coronavirus variants could cause more reinfections, require updated vaccines. Science | AAAS. https://www.sciencemag.org/news/2021/01/new-coronavirus-variants-could-cause-more-reinfections-require-updated-vaccines
This variant presents 14 non-synonymous mutations, 6 synonymous mutations and 3 deletions. The multiple mutations present in the viral RNA encoding for the spike protein (S) are of most concern, such as the deletion Δ69-70, deletion Δ144, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H
What would be the limit of detection of the new variants in the wastewater by this NGS based sequencing method?
If you would like a process management tool with a lot of features, including tmux support, restarting and killing individual processes and advanced configuration, you should take a look at Hivemind's big brother — Overmind!
If a lot of those features seem like overkill for you, especially the tmux integration, you should take a look at Overmind's little sister — Hivemind!
// `lodash/padStart` accepts an optional `chars` param. _.padStart('a', 3, '-') // ➜ '--a' // `lodash/fp/padStart` does not. fp.padStart(3)('a'); // ➜ ' a'
The lodash/fp module promotes a more functional programming (FP) friendly style by exporting an instance of lodash with its methods wrapped to produce immutable auto-curried iteratee-first data-last methods.
variant id lookup result: http://localhost:8001/test.html
Blokland, I. V. van, Lanting, P., Ori, A. P., Vonk, J. M., Warmerdam, R. C., Herkert, J. C., Boulogne, F., Claringbould, A., Lopera-Maya, E. A., Bartels, M., Hottenga, J.-J., Ganna, A., Karjalainen, J., Study, L. C.-19 cohort, Initiative, T. C.-19 H. G., Hayward, C., Fawns-Ritchie, C., Campbell, A., Porteous, D., … Franke, L. H. (2020). Using symptom-based case predictions to identify host genetic factors that contribute to COVID-19 susceptibility. MedRxiv, 2020.08.21.20177246. https://doi.org/10.1101/2020.08.21.20177246
Qu, J., Cai, Z., Liu, Y., Duan, X., Han, S., Zhu, Y., Jiang, Z., Zhang, Y., Zhuo, C., Liu, Y., Liu, Y., Liu, L., & Yang, L. (2020). Persistent bacterial coinfection of a COVID-19 patient caused by a genetically adapted Pseudomonas aeruginosa chronic colonizer. BioRxiv, 2020.08.05.238998. https://doi.org/10.1101/2020.08.05.238998
One representative example, from the U.S. Navy, is "COMCRUDESPAC", which stands for "commander, cruisers destroyers Pacific"; it is also seen as "ComCruDesPac"
ComCruDesPac is much preferrable. Just like I prefer CoViD-19 over COVID-19, so you can actually visually see the 3 words that the acronym is built from.
Yurkovetskiy, L., Wang, X., Pascal, K. E., Tomkins-Tinch, C., Nyalile, T., Wang, Y., Baum, A., Diehl, W. E., Dauphin, A., Carbone, C., Veinotte, K., Egri, S. B., Schaffner, S. F., Lemieux, J. E., Munro, J., Rafique, A., Barve, A., Sabeti, P. C., Kyratsous, C. A., … Luban, J. (2020). Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant. BioRxiv, 2020.07.04.187757. https://doi.org/10.1101/2020.07.04.187757
The aim of this list is to document all Markdown syntax variations (rather than implementations).
variant id lookup result: https://www.ncbi.nlm.nih.gov/clinvar/variation/692266/
variant id lookup result: https://www.ncbi.nlm.nih.gov/clinvar/variation/692269/
variant id lookup result: https://www.ncbi.nlm.nih.gov/clinvar/variation/692269/
variant id lookup result: https://www.ncbi.nlm.nih.gov/clinvar/variation/692266/
variant id lookup result: https://www.ncbi.nlm.nih.gov/clinvar/variation/692268/
variant id lookup result: https://www.ncbi.nlm.nih.gov/clinvar/variation/692266/
variant id lookup result: https://www.ncbi.nlm.nih.gov/clinvar/variation/692266/
Πατρὸς
Note the juxtaposed prosodic variants:
variant id lookup result: https://www.ncbi.nlm.nih.gov/clinvar/variation/547946/
variant id lookup result: https://www.ncbi.nlm.nih.gov/clinvar/variation/692227/
variant id lookup result: https://www.ncbi.nlm.nih.gov/clinvar/variation/547947/
variant id lookup result: https://www.ncbi.nlm.nih.gov/clinvar/variation/547947/
variant id lookup result: https://www.ncbi.nlm.nih.gov/clinvar/variation/599396/
variant id lookup result: https://www.ncbi.nlm.nih.gov/clinvar/variation/692228/
variant id lookup result: https://www.ncbi.nlm.nih.gov/clinvar/variation/634924/
variant id lookup result: https://www.ncbi.nlm.nih.gov/clinvar/variation/545116/
fata
data
variant id lookup result: https://www.ncbi.nlm.nih.gov/clinvar/variation/559601/
variant id lookup result
variant id lookup result
variant id lookup result
Introduction to Population Genetics